Flat dose (175 mg/weekly) paclitaxel: Pharmacokinetics and clinical implications

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 12, 2005, Pages 601-602

  Mross, K ^a,c   Hollander N ^b   Unger, C ^a   Massing, U ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Department Medical Oncology   (Germany)

Author keywords

Flat dose; Paclitaxel; Pharmacokinetics

Indexed keywords

BILIRUBIN; LIVER ENZYME; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMED CONSENT; LIVER DYSFUNCTION; SOLID TUMOR;

EID: 29444458219     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43601     Document Type: Article

References (9)

1. Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A 2002 Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20: 574-581
2. Mielke S, Sparreboom A, Steinberg S, Gelderblom H, Unger C, Behringer D, Mross K 2005 Association of paclitaxel pharmacokinetics with the development of a peripheral neuropathy in patients with advanced cancer. Clinical Cancer Res 11: 4843-4850
3. Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H 1997 Clinical phase I study with 1-hour paclitaxel infusion. Ann Oncol 9: 569-572
4. Mross K, Holländer N, Hauns B, Schumacher M, Maier-Lenz H 2000 The pharmacokinetics of an one-hour paclitaxel infusion. Cancer Chemother Pharmacol 45: 463-470
5. Mross K, Häring B, Holländer N, Mielke S, Behringer D, Unger C 2002 Comparison of the 1-hour and 3-hour paclitaxel infusion pharmacokinetics: results from a randomised trial. Onkologie 25: 503-510
6. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Naughton M, Norton L, Winer E, Hudis C 2004 C CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3-hour infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab for HER2 positive MBC and randomized for trastuzumab in HER2 normal MBC. J Clin Oncol 22 (14S): 512
7. Smorenburg CH, Verweij J, Bontenbal M, Mross K, van Zomeren DM, Seynaeve C, Sparreboom A 2003 Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 39: 196-202
8. Sparreboom A, Marsh S, Henningsson A, Karllson MO, Loos WJ, Garsa A, Mross K, Mielke S, Vigano L, Loatelli A, Verweij J, McLeod HL 2005 Effect of CYP2C8, CYP4A4, CYP3A5, and ABCB1 polymorphisms on the pharmacokinetics of paclitaxel. Clin Cancer Res 11 (in press)
9. Van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WL, Sparreboom A 2000 Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anticancer Drugs 11: 331-337